FDA Recalls · August 21, 2026 · Primary source
Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
Read the full document at FDA Recalls.
What this may mean
The recall covers a single lot of Thyroid Tablets USP 30 mg distributed to the consumer level, requiring removal of the affected product from pharmacy and distributor shelves. Pharmacies, PBMs, and dispensing providers holding Lot No. 504950 are subject to the recall action. The superpotency finding implicates GMP compliance obligations under 21 CFR Part 211.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Recalls · August 20, 2026Optimal Balance Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin LevelsScore 68
- FDA Recalls · October 7, 2026Nova Biomedical® Announces Global Medical Device Correction for StatStrip® Glucose Hospital MeterScore 48
- FDA Recalls · August 28, 2026B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container Due to the Presence of Particulate MatterScore 48
- FDA Recalls · September 4, 2026American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of SterilityScore 46
- FDA Recalls · August 25, 2026Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection Due to Potential Presence of Particulate MatterScore 43
- FDA Recalls · August 20, 2026B. Braun Medical Inc. Issues Voluntary North American Recall of Excel® Lactated Ringers Injection, 1000mL Due to the Presence of Particulate MatterScore 43